Actelion / Johnson & Johnson: Tendered Vs Untendered Lines
Any deal-threatening risks to the Actelion / Johnson & Johnson transaction were assuaged in late March and we now solely await EC antitrust...
367 Views
Actelion / Johnson & Johnson: Trading Idorsia, the R&D NewCo Spin-Off
J&J recent declared its tender offer for Actelion successful and we are now in the midst of the additional acceptance period which runs from...
427 Views
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
AML represents one of the largest hematologic cancer populations with one of the worst survival rates. Global prevalence is expected to increase at...
522 Views
American Society of Hematology- (ASH) Annual Conference (2016) Review
We reviewed data presented at the American Society of Hematology (ASH) conference in San Diego last week with a focus on the evolving treatment...
363 Views
American Society of Hematology (ASH) -Annual Conference (2016) Preview
With a focus on novel mechanisms of action (MoA), we highlight select non-Hodgkin's lymphoma (NHL) and Multiple Myeloma (MM) related abstracts at...
227 Views